I am thinking that NP's discussion on Thursday's CC regarding BTD for triple negative breast cancer will have to do with supplementing the submission to reflect patient 5 info. While I don't love potentially restarting the 60 day period, I do love the notion that five great sets of data will almost ensure FDA approval.